GeneThera Offered World Wide Rights to E.coli Vaccine From the University of New Mexico


Posted 06 October 2008 @ 06:00 am EST

Source of Article:

WHEAT RIDGE, CO -- (Marketwire) -- 10/06/08 -- GeneThera, Inc. (PINKSHEETS: GTHR)announced today that it is in negotiations with the University of NewMexico for world wide development and distribution rights to a vaccinedeveloped there that is designed to significantly inhibit the carriage andshedding of the E.coli bacteria in cattle.

According to University sources, the vaccine is comprised of "LiveAttenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding ofEnterohemorrhagic Escherichia Coli in Cattle"

In the most recent case, the U.S. Agriculture Department, on August 11,said, "Omaha meat packing company Nebraska Beef Ltd is recalling 1.2million pounds of beef because it may be contaminated with a particularlydangerous strain of E.coli."

According to the Associated Press, dated February 17, 2008, "The U.S.Department of Agriculture is ordering the recall of 143 million pounds offrozen beef from aCalifornia slaughterhouse. Officials say it's the largest beef recall inthe United States,surpassing a 1999 ban of 35 million pounds of ready-to-eat meats. Therecall will affect beef products dating to February 1st, 2006."

Commenting on the news, GeneThera Chairman Dr. Tony Milici, MD, PhD stated,"I look forward to finalizing the agreement with the University of NewMexico regarding the E.coli vaccine license rights. I believe this is agreat opportunity for GeneThera to continue developing molecular tests andtherapeutics to better detect and control the spread of E.coli 0157:H7.This could have profound effects on increasing the safety of our meatsupply worldwide... not to mention the millions of dollars it could savethe beef industry by reducing occurrences of E.coli contamination."

If an agreement is reached between GeneThera and the University of NewMexico, it will mean GeneThera will have "exclusive rights to make, use,and sell" the vaccine on a world wide basis.


GeneThera, Inc. is a molecular biotechnology company located in WheatRidge, CO. The Company provides genetic diagnostic solutions for theveterinary and agricultural industries with future plans to include thehealth-care industry. The Company's proprietary diagnostic solution isbased on a genetic expression system, GES, a protocol designed to functionon a highly automated Fluorogenic PCR platform. This platform enablesGeneThera to offer tests that are presently not available from othertechnologies. The GES is designed for a host of individual diseases, thecurrent priority being Mad Cow disease, Chronic Wasting Disease, E.Coli0157:H7 and Johne's disease, all diseases affecting cattle worldwide.

This press release contains forward-looking statements, which are madepursuant to the Safe-Harbor provisions of the Private Securities LitigationReform Act of 1995. Words such as "intends," "believes," and similarexpressions reflecting something other than historical fact are intended toidentify forward-looking statements, but are not the exclusive means ofidentifying such statements. These forward-looking statements involve anumber of risks and uncertainties, including the timely development andmarket acceptance of products and technologies, the ability to secureadditional sources of finance, the ability to reduce operating expenses,and other factors described in the Company's filings with the Securitiesand Exchange Commission. The actual results that the Company achieves maydiffer materially from any forward-looking statement due to such risks anduncertainties. The Company undertakes no obligation to revise or update anyforward-looking statements in order to reflect events or circumstances thatmay arise after the date of this release.

Contact:GeneThera, Inc.Dr. Tony Milici303-463-6371



Main Page

setstats            Copyright (C) All rights reserved under

            If you have any comments, please  send your email to